Cargando…

Evaluation of disability in patients exposed to fluoroquinolones

BACKGROUND: Fluoroquinolones are used for conditions including sinusitis, bronchitis, and urinary tract infections. It has been suggested that exposure to fluoroquinolones for these conditions is associated with disability resulting from adverse events in 2 or more organ systems. The objectives were...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilcox, Marsha A., Villasis-Keever, Angelina, Sena, Anthony G., Knoll, Christopher, Fife, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268406/
https://www.ncbi.nlm.nih.gov/pubmed/32493505
http://dx.doi.org/10.1186/s40360-020-00415-4
_version_ 1783541611482841088
author Wilcox, Marsha A.
Villasis-Keever, Angelina
Sena, Anthony G.
Knoll, Christopher
Fife, Daniel
author_facet Wilcox, Marsha A.
Villasis-Keever, Angelina
Sena, Anthony G.
Knoll, Christopher
Fife, Daniel
author_sort Wilcox, Marsha A.
collection PubMed
description BACKGROUND: Fluoroquinolones are used for conditions including sinusitis, bronchitis, and urinary tract infections. It has been suggested that exposure to fluoroquinolones for these conditions is associated with disability resulting from adverse events in 2 or more organ systems. The objectives were to: describe: 1) fluoroquinolone, azithromycin, and sulfamethoxazole / trimethoprim utilization for these infections; 2) the rate of disability associated with exposure to each of these antibiotic classes and adverse events in 2 or more system organ classes, and 3) compare outcome rates for each of the antibiotic classes. METHODS: This study was conducted using administrative data to mitigate the limitations of spontaneous reports. The sampling frame was a U.S. population with both medical and disability insurance, including patients with the above uncomplicated infections who were prescribed the antibiotics of interest. The primary outcome was an incident short-term disability claim associated with adverse events in 2 different organ systems within 120 days of exposure. A matched analysis was used to compare the outcome for patients receiving each of the drug classes. RESULTS: After propensity score matching, there were 119,653 individuals in each of the exposure groups. There were 264 fluoroquinolone associated disability events and 243 azithromycin/ sulfamethoxazole associated disability events (relative risk =1.09 (95% CI: 0.92–1.30; calibrated p = 0.84)). The results were not significantly different from the null hypothesis of no difference between groups. CONCLUSION: Comparative assessments are difficult to conduct in spontaneous reports. This examination of disability associated with adverse events in different system organ classes showed no difference between fluoroquinolones and azithromycin or sulfamethoxazole in administrative data.
format Online
Article
Text
id pubmed-7268406
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72684062020-06-07 Evaluation of disability in patients exposed to fluoroquinolones Wilcox, Marsha A. Villasis-Keever, Angelina Sena, Anthony G. Knoll, Christopher Fife, Daniel BMC Pharmacol Toxicol Research Article BACKGROUND: Fluoroquinolones are used for conditions including sinusitis, bronchitis, and urinary tract infections. It has been suggested that exposure to fluoroquinolones for these conditions is associated with disability resulting from adverse events in 2 or more organ systems. The objectives were to: describe: 1) fluoroquinolone, azithromycin, and sulfamethoxazole / trimethoprim utilization for these infections; 2) the rate of disability associated with exposure to each of these antibiotic classes and adverse events in 2 or more system organ classes, and 3) compare outcome rates for each of the antibiotic classes. METHODS: This study was conducted using administrative data to mitigate the limitations of spontaneous reports. The sampling frame was a U.S. population with both medical and disability insurance, including patients with the above uncomplicated infections who were prescribed the antibiotics of interest. The primary outcome was an incident short-term disability claim associated with adverse events in 2 different organ systems within 120 days of exposure. A matched analysis was used to compare the outcome for patients receiving each of the drug classes. RESULTS: After propensity score matching, there were 119,653 individuals in each of the exposure groups. There were 264 fluoroquinolone associated disability events and 243 azithromycin/ sulfamethoxazole associated disability events (relative risk =1.09 (95% CI: 0.92–1.30; calibrated p = 0.84)). The results were not significantly different from the null hypothesis of no difference between groups. CONCLUSION: Comparative assessments are difficult to conduct in spontaneous reports. This examination of disability associated with adverse events in different system organ classes showed no difference between fluoroquinolones and azithromycin or sulfamethoxazole in administrative data. BioMed Central 2020-06-03 /pmc/articles/PMC7268406/ /pubmed/32493505 http://dx.doi.org/10.1186/s40360-020-00415-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Wilcox, Marsha A.
Villasis-Keever, Angelina
Sena, Anthony G.
Knoll, Christopher
Fife, Daniel
Evaluation of disability in patients exposed to fluoroquinolones
title Evaluation of disability in patients exposed to fluoroquinolones
title_full Evaluation of disability in patients exposed to fluoroquinolones
title_fullStr Evaluation of disability in patients exposed to fluoroquinolones
title_full_unstemmed Evaluation of disability in patients exposed to fluoroquinolones
title_short Evaluation of disability in patients exposed to fluoroquinolones
title_sort evaluation of disability in patients exposed to fluoroquinolones
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268406/
https://www.ncbi.nlm.nih.gov/pubmed/32493505
http://dx.doi.org/10.1186/s40360-020-00415-4
work_keys_str_mv AT wilcoxmarshaa evaluationofdisabilityinpatientsexposedtofluoroquinolones
AT villasiskeeverangelina evaluationofdisabilityinpatientsexposedtofluoroquinolones
AT senaanthonyg evaluationofdisabilityinpatientsexposedtofluoroquinolones
AT knollchristopher evaluationofdisabilityinpatientsexposedtofluoroquinolones
AT fifedaniel evaluationofdisabilityinpatientsexposedtofluoroquinolones